Abbonarsi

Phenotypic differences of chronic angiotensin II/phenylephrine infusion in C57BL/6J and C57BL/6N mouse strains - 21/05/25

Doi : 10.1016/j.acvd.2025.03.072 
Zhenyi Zhao 1, , Iman Momken 2, Mathias Mericskay 1
1 Inserm UMRS-1180 signalisation et physiopathologie cardiovasculaire, faculté de pharmacie, université Paris-Saclay, Orsay, France 
2 Inserm Carpat u1180, faculté de pharmacie, université Paris-Saclay, Châtenay-Malabry, France 

Corresponding author.

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.

Si connetta per beneficiarne

Summary

Introduction

Hypertension is present in 75% of patients suffering heart failure with preserved ejection fraction (HFpEF) patients while obesity is present in average in only 30–40%. Angiotensin II/phenylephrine (ANGII/PE) infusion in mice is a new model of HFpEF without obesity [1]. The C57BL/6J (B6J) and C57BL/6N (B6N) inbred substrains are frequently used to study pathological models. The metabolic phenotypic differences between B6J and BL6N are considered to be influenced by the nicotinamide nucleotide transhydrogenase (Nnt) gene, which is found only in B6J. Nnt is a key antioxidative enzyme based on its ability to regenerate NADPH from NADH.

Objective

We aim to compare the effects of ANG II/PE infusion on B6J and B6N mice.

Method

Male mice (8 week-old) were implanted with an osmotic minipump to allow continuous infusion of ANG II/PE for 21 days. Echocardiography was performed at 19/20 days. Cardiac hypertrophy and fibrosis were evaluated by histological methods and by qRT-PCR and Western blot. Mitochondrial respiration was assessed by oxygrqphy and NAD was quantified by the alcohol dehydrogenase cycling assay.

Results

Radial fractional shortening was preserved in B6J-ANGII/PE and LVEF (B-mode) was moderately reduced to 43 vs. 61% in control (saline) group, while both parameters were severely reduced in B6N mice. AngII/PE significantly increased E/A ratio in B6J that exhibited concentric hypertrophy, whereas B6N mice exhibited eccentric hypertrophy and A wave was not detected. Lung weight to tibia length ratio was increased in both strains. B6N mice showed more severe cardiac fibrosis and hypertrophy. Increased protein expression of Pparg coactivator 1 alpha (PGC-1α) and Sirtuin1 was observed with AngII/PE in B6N mice only. There was no significant difference in mitochondrial oxidative capacity and NAD levels between B6N and B6J mice and no impact of the treatment.

Conclusion

With AngII/PE infusion, B6J mice presented features of HF with mid-range EF while B6N mice developed HF with reduced ejection fraction (HFrEF). This new model provides an angle to study the divergent pathophysiological pathways of HFpEF vs HFrEF in the context of hypertension. Our future studies will also aim to identify the different molecular mechanisms of B6J and B6N mice under thispathological stimulation and explore biological sex differences.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


© 2025  Pubblicato da Elsevier Masson SAS.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 118 - N° 6-7S1

P. S207 - giugno 2025 Ritorno al numero
Articolo precedente Articolo precedente
  • Distinct Ca2+ handling modulation in a rat model of right hypertrophy and dysfunction in response to mild or severe pulmonary artery constriction
  • Pauline Le Gourriérec, Kristelle El Jekmek, Angele Boet, Antoine Beauvais, David Montani, Olaf Mercier, Fabrice Antigny, Jessica Sabourin
| Articolo seguente Articolo seguente
  • Could cardiac rehabilitation be relevant for patients with end-stage heart failure treated by continuous IV dobutamine in destination therapy?
  • Charlotte Hulin-Delmotte, Nathalie Charlotte, Xavier Balaire, Aurélie Bardet

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.